Loading the section
Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Insulet Corporation trades on Nasdaq under the ticker PODD. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks PODD has traded between 126.40 $ and 354.88 $. As of 09 October 2026 the price stood 3.89 % of the way from the 52-week low to the high.
Over one year PODD shares fell 57.12 %; over six months they fell 31.31 %. Volatility over 90 days is 52.78 %. Dividends are not included: this is price change only, as of 09 October 2026.
PODD trades at a price-to-earnings ratio of 31.1, above the sector median of 24.8. Price to sales is 3.3, below the sector median of 3.9. Price to book is 7.2, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 134.19 | 137.17 | 133.72 | 135.28 | 864,469 |
| 08 October 2026 | 133.96 | 134.60 | 132.86 | 134.47 | 2M |
| 07 October 2026 | 134.94 | 137.10 | 133.33 | 134.36 | 1M |
| 06 October 2026 | 135.77 | 136.16 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Insulet makes an insulin pump with no tubing — it sticks straight onto the skin.
An ordinary pump connects to the body by tubing and hangs on a belt; that is awkward and visible. Here the reservoir and mechanism are combined in a small pod that attaches to the skin and is replaced every few days. It is controlled from a phone, and dosing is calculated automatically from glucose sensor data.
The economics are effectively a subscription: the pod is disposable, and revenue recurs while the patient uses the system. The market is expanding from type 1 diabetes into type 2, where patients are an order of magnitude more numerous. Risks: competition from pump and drug makers, insurer reimbursement decisions and the cost of the disposable part. The company pays no dividend.
Address:100 NAGOG PARK, ACTON, MA, 01720, US
Insulet Corporation reported revenue of 2.9B $ and net income of 303M $ over the last four quarters. Net margin is 10.44 %. Revenue changed by +31.92 % year over year. Earnings per share are 4.28 $. Market capitalisation is 9.4B $.
PODD has a return on equity of 23.25 %, above the sector median of −41.68 %. Return on assets is 10.14 %, above the sector median of −32.11 %. Operating margin is 17.48 %, above the sector median of −26.84 %.
| 325M |
| DXCMDexCom, Inc. | 84.15 | −0.31 % | 324M |
| MDLNMedline Inc. | 36.26 | +1.45 % | 297M |
| RMDResMed Inc. | 230.43 | +1.63 % | 276M |
| WSTWest Pharmaceutical Services, Inc. | 368.78 | +1.52 % | 207M |
| 133.73 |
| 134.73 |
| 2M |
| 05 October 2026 | 131.69 | 135.81 | 131.23 | 135.62 | 2M |
| 02 October 2026 | 131.83 | 132.53 | 128.01 | 131.69 | 3M |
| 01 October 2026 | 131.78 | 132.02 | 128.75 | 130.79 | 3M |
| 30 September 2026 | 132.93 | 133.15 | 130.10 | 130.47 | 1M |
| 29 September 2026 | 132.58 | 133.49 | 130.80 | 132.84 | 1M |
| 28 September 2026 | 134.44 | 135.40 | 130.39 | 133.11 | 2M |
| 25 September 2026 | 135.78 | 138.06 | 134.48 | 136.13 | 1M |
| 24 September 2026 | 136.80 | 139.35 | 134.55 | 135.78 | 1M |
| 23 September 2026 | 139.07 | 139.82 | 134.73 | 136.49 | 1M |
| 22 September 2026 | 141.93 | 142.04 | 137.60 | 139.38 | 1M |
| 21 September 2026 | 140.60 | 141.49 | 138.59 | 140.53 | 1M |
| 18 September 2026 | 141.25 | 142.17 | 139.96 | 140.60 | 3M |
| 17 September 2026 | 140.38 | 141.80 | 138.51 | 141.55 | 1M |
| 16 September 2026 | 138.86 | 143.45 | 138.11 | 140.60 | 1M |
| 15 September 2026 | 137.59 | 140.28 | 136.16 | 139.24 | 1M |
| 14 September 2026 | 134.23 | 137.98 | 131.61 | 137.80 | 2M |